Read all articles

Appointment recognises Andy’s decade-long contribution to RSA, including team development, scientific expertise and role in building the firm’s West Coast business.

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Using machine learning to identify responsive trial participants reduces patient drop-out and de-risks development timelines. We explore the data-fluent leaders driving this shift.

The clinical validation of next-generation oncology therapeutics brings hope to difficult-to-treat cancers. Sourcing medical directors specialised in solid tumours is critical.

Integrating biomarkers early in drug development improves patient stratification and trial success. Sourcing diagnostic leaders who understand drug-diagnostic co-development is key.

The shift from injectable to oral GLP-1 formulations is transforming the metabolic sector. Discover the commercialisation capabilities required to lead these multi-billion pound launches.